return to corporate website
Menu
Return to
www.noxopharm.com
Home
About Us
About Noxopharm
Board of Directors
Management Team
Scientific Advisors
Corporate Governance
Company Constitution
Sustainability
Noxopharm History
Research and Clinical Programs
Research and Clinical Programs
About Pharmorage
Investor Centre
Share Price
ASX Announcements
Why Invest in Noxopharm
Presentations & Interviews
Annual Reports
Financial Reports
Analyst Reports
Investor Fact Sheet
Investor FAQs
Upcoming Events
Privacy Policy
Share Registry Information
Media Centre
Overview
Newsletters
Coverage
Investor Videos
NOX Insights
Noxopharm Podcasts
Contact Us
Contact Us
Partnering
Working at Noxopharm
Newsletter Email Alerts
ASX Announcements Email Alerts
Investor Centre
Home
>
Investor Centre
>
ASX Announcements
Share Price
ASX Announcements
Why Invest in Noxopharm
Presentations & Interviews
Annual Reports
Financial Reports
Analyst Reports
Investor Fact Sheet
Investor FAQs
Upcoming Events
Privacy Policy
Share Registry Information
ASX Announcements
Filter by Year:
2022
2021
2020
2019
2018
2017
2016
21-Feb-2020
Appendix 2A
21-Feb-2020
FDA grants IND approval to Veyonda
18-Feb-2020
Termination of Convertible Loan
18-Feb-2020
Section 708 Certificate
18-Feb-2020
Appendix 2A
18-Feb-2020
Noxopharm Alliance With GenesisCare
14-Feb-2020
Proposed issue of Securities - NOX
14-Feb-2020
$8.1M Financing & Re-Set of Capital Structure
14-Feb-2020
Pronounced survival benefit in LuPIN interim trial data
12-Feb-2020
Trading Halt
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
Next
